June 11, 2025 a 08:38 pm
LLY: Analysts Ratings - Eli Lilly and Company
Eli Lilly and Company, a global leader in pharmaceuticals, shows dynamic movement in analyst ratings. Recent trends suggest robust buying interest balanced with cautious holds. Analysts continue to evaluate Eli Lilly's diverse portfolio ranging from diabetes to cancer treatments, highlighting crucial aspects that could influence investment decisions.
Historical Stock Grades
Examining the latest analyst ratings for Eli Lilly as of June 2025, we observe a mix of sentiment characterized by a dominant 'Buy' recommendation, complemented by a strong 'Strong Buy' interest. A slight presence of 'Hold', 'Sell', and 'Strong Sell' indicates a cautious optimism among analysts.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 7 | |
| Buy | 16 | |
| Hold | 5 | |
| Sell | 1 | |
| Strong Sell | 1 |
Sentiment Development
Over recent months, Eli Lilly's analyst ratings reflect a steady sentiment with occasional fluctuations. An observable reduction in 'Strong Buy' ratings suggests a tempered enthusiasm while 'Hold' ratings indicate cautious analysis amidst market conditions.
- The total number of recommendations remains relatively constant, pointing to enduring interest.
- 'Buy' ratings show resilience, with minor oscillations in 'Strong Buy'.
- 'Hold' ratings have decreased gradually, indicative of evolving analyst opinions.
Percentage Trends
Percentage analysis reveals subtle shifts in analyst sentiment. The 'Hold' category exhibits a contraction while 'Buy' remains stable.
- 'Strong Buy' ratings decreasing from 20% to around 15% reflects restraint.
- 'Buy' consistently holds approximately 50%, demonstrating strong confidence.
- A slight increase in 'Sell' ratings suggests emerging caution in market attitudes.
Noteworthy changes include the increase in buy interest indicating optimism, counterbalanced by caution evident in 'Hold' and 'Sell' adaptations.
Latest Analyst Recommendations
The latest analyst reviews for Eli Lilly show a mixture of maintained recommendations alongside a few shifts in sentiment, indicative of market volatility and strategic evaluations.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-02 | Buy | Buy | UBS |
| 2025-04-28 | Reduce | Buy | HSBC |
| 2025-04-14 | Buy | Buy | Guggenheim |
| 2025-04-09 | Overweight | Overweight | Morgan Stanley |
| 2025-04-08 | Buy | Neutral | Goldman Sachs |
Analyst Recommendations with Change of Opinion
Tracking shifts in opinion, we see fluctuating analyst sentiment, with some downgrades indicating caution and upgrades highlighting perceived value improvements.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-28 | Reduce | Buy | HSBC |
| 2025-04-08 | Buy | Neutral | Goldman Sachs |
| 2024-08-12 | Buy | Hold | Deutsche Bank |
| 2024-04-03 | Buy | Hold | Erste Group |
| 2024-02-21 | Hold | Buy | DZ Bank |
Interpretation
The sentiment analysis of Eli Lilly suggests a mixed yet predominantly positive assessment. The presence of 'Strong Buy' and 'Buy' recommendations underscores a solid confidence in Eli Lilly's market trajectory despite economic uncertainties. The stability of these analyses reflects consistent market positioning, though recent fluctuations hint at underlying volatility. The balance of opinions suggests that while there is confidence in Eli Lilly's prospects, there's also an acknowledgment of sector and market challenges.
Conclusion
Eli Lilly's stock, bolstered by a diverse portfolio, remains a significant contender in the pharmaceutical sector. Current analyst reviews affirm Eli Lilly's stable yet potent market presence, with consistent 'Buy' ratings supporting potential growth avenues. However, the presence of cautious recommendations such as 'Hold' and sporadic 'Reduce' indicates market vigilance. Overall, the outlook remains promising, as analysts weigh Eli Lilly's innovations against broader market trends.